Clinical trials: Human Factors
Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
This phase I/II trial study evaluates the tolerability and best tolerated dose of the PI3K inhibitor GDC-0941 when given with the chemotherapy cisplatin.
- Conditions
- Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01918306
- Testing
- cisplatin, laboratory biomarker analysis, pharmacological study
- Where
- 16 sites in United States
- Volunteers
- 11 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Human Risk Factors, Driving Behavior
The Efficacy of a Functional Meta-Cognitive Intervention to Improve Human Factors of Professional Drivers
The objective of the study is to examine the effectiveness of a functional-meta-cognitive intervention program to reduce driving risk factors amongst professional bus drivers.
- Conditions
- Human Risk Factors, Driving Behavior, Meta-cognition
- Trial name
- NCT02903147
- Testing
- Functional Meta-Cognitive Intervention, The employer's training
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Tel Aviv University
Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients
In the second-line treatment setting for MBC, many agents, including antitubulin drugs (Taxanes, Vinorelbine) and antimetabolites (Capecitabine, Gemcitabine), have demonstrated activity, but no agent is clearly superior.
- Trial name
- GIM11-BERGI (NCT02175446)
- Testing
- Bevacizumab and eribulin
- Where
- 17 sites in Italy
- Volunteers
- 61 people
- Sponsor
- Consorzio Oncotech
Metastatic Breast Cancer, Breast Cancer
Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer
This is a multi-center, randomized, open-label, parallel group study designed to evaluate efficacy and safety of fulvestrant followed, at progression, by examestane and everolimus versus examestane and everolimus followed, at…
- Conditions
- Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Trial name
- FEVEX (NCT02404051)
- Testing
- Everolimus, Exemestane, Fulvestrant
- Where
- 41 sites in Italy
- Volunteers
- 745 people
- Sponsor
- Consorzio Oncotech
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer
Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT01288261
- Testing
- paclitaxel, bavituximab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Arizona
Estrogen Receptor Negative (ER-Negative) Breast Cancer, Progesterone Receptor Negative (PR-Negative) Breast Cancer
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
The purpose of the study is to investigate the response rate for triple negative breast cancer patients with brain metastasis when INIPARIB is used in combination with irinotecan.
- Conditions
- Estrogen Receptor Negative (ER-Negative) Breast Cancer, Progesterone Receptor Negative (PR-Negative) Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer, Brain Metastases
- Trial name
- NCT01173497
- Testing
- INIPARIB + irinotecan
- Where
- 13 sites in United States
- Volunteers
- 44 people
- Sponsor
- Sanofi
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients
This is a phase II comparative randomized clinical trial. Eligible patients will be randomized (1:1) to: Arm A: Myocet plus Cyclofosfamide plus Metformin Arm B: Myocet plus Cyclofosfamide Statistical Considerations: In this…
- Trial name
- MYME (NCT01885013)
- Testing
- Metformin + Myocet + Cyclophosphamide, Myocet + Cyclophosphamide
- Where
- 25 sites in Italy
- Volunteers
- 126 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients
Human epidermalgrowth factor receptor-2(HER2) negative Luminal B subtype breast cancer patients are included. After 4 cycles of Capecitabine combined with Docetaxel(XT) protocol neoadjuvant chemotherapy ,those who reach partial…
- Trial name
- NCT01779531
- Where
- China
- Volunteers
- 640 people
- Sponsor
- Guangdong Academy of Medical Sciences